Home Conference Coverage ASH Conference Coverage

ASH Conference Coverage

COMPARE CRUSH: Integral and Crushed Pills Same for TIMI Flow Post-PCI

Are Oral Anticoagulants Effective Against VTE in Patients with Multiple Myeloma?

Social Determinants Affect Cancer Health Equity

Insurance Status Linked to Survival for Patients with Multiple Myeloma

CAR T-Cell Therapy Cost-Effective for Pediatric ALL

P-BCMA-101 CAR T is Effective and Safe for Refractory Myeloma, Even at Lower Doses

Multiple myeloma - blood disorder abstract.

Patients with High-Risk Multiple Myeloma May Be Missed Without Gene Expression Profiling

Prognostic Value of Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity

LUMMICAR-2: CT053 BCMA CAR T Is Active in Refractory Myeloma, But Toxicity Persists

gene therapy

Subcutaneous Daratumumab Regimen Improves PFS in Pre-Treated Myeloma

Dr. Callaghan Talks About HAVEN Study Investigating Emicizumab in Patients with Hemophilia A

Dr. Callaghan Talks About HAVEN Study Investigating Emicizumab in Patients with Hemophilia A

Doctor giving emotional support to a senior patient using face mask

Systematic Review Compares Allogeneic Hematopoietic Cell Transplant Versus Gene Therapy in Sickle Cell Disease

An African senior gentleman speaks with his doctor during a routine check-up in the doctors office

Zeta Globin Gene Expression May Lead to Therapy for Alpha Thalassemia Major

Female doctor consulting with male patient.

Long-Term Data Support AMT-060 Gene Therapy in Hemophilia B

Load more
Subscribe to RSS